A Phase II Study of IMMU 130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Metastatic Colorectal Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
Price : $35 *
At a glance
- Drugs Labetuzumab govitecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Sponsors Immunomedics
- 18 Jan 2017 Results published in an Immunomedics media release.
- 18 Jan 2017 Status changed from not yet recruiting to active, no longer recruiting, as reported by an Immunomedics media release.
- 22 Aug 2013 This trial is expected to start in the first quarter of 2014, according to an Immunomedics media release.